

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

CLARIFICATION ANNOUNCEMENT IN RELATION TO CLOSURE OF THE REGISTER OF MEMBERS

Reference is made to the circular of the Company dated 12 March 2025 (the “**Circular**”) containing the notice of the special general meeting of the Company (the “**SGM Notice**”) in relation to the proposed appointment of auditor of the Company (the “**SGM**”) to be held on Friday, 28 March 2025. Unless otherwise specified, the terms used in this announcement shall have the same meanings as those defined in the Circular.

The Company noted an inadvertent clerical error in the SGM Notice and wishes to clarify that there will be no closure of register of members for the SGM. As such, note (5) on the SGM Notice shall be deleted in its entirety and be replaced as follows:

“The register of members of the Company will not be closed for the purpose of determining the entitlement to attend and vote at the special general meeting (the “**SGM**”) of the Company. For the purpose of determining the identity of the members entitled to attend and vote at the SGM, the record date is on Friday, 28 March 2025. In order to qualify for attending and voting at the SGM, all transfers of Shares accompanied by the relevant share certificates and properly completed transfer forms must be lodged with the branch share registrar and transfer agent of the Company in Hong Kong, Tricor Tengis Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, not later than 4:30 p.m. on 27 March 2025.”

Save as disclosed above, all other information and contents set out in the Circular and the SGM Notice shall remain unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Circular and the SGM Notice.

By order of the Board
Innovative Pharmaceutical Biotech Limited
Jiang Nian
Chairman

Hong Kong, 13 March 2025

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Mr. Li Jiehong (executive Director), Ms. Qi Shujuan (executive Director), Ms. Chen Weijun (independent non-executive Director), Mr. Wang Rongliang (independent non-executive Director) and Mr. Chen Jinzhong (independent non-executive Director).